Zymeworks Stock-Based Compensation Growth & History (ZYME)

Zymeworks's stock-based compensation was $28.0M for fiscal 2025.

View full Zymeworks company overview

Zymeworks annual stock-based compensation history

Zymeworks annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20252025-12-31$28.0M$10.2M+57.57%
20242024-12-31$17.8M$9.7M+119.60%
20232023-12-31$8.1M$4.1M+101.79%
20222022-12-31$4.0M−$6.7M−62.67%
20212021-12-31$10.8M−$18.4M−63.06%
20202020-12-31$29.1M

Zymeworks stock-based compensation trends

Over the last five fiscal years, Zymeworks's stock-based compensation decreased from $29.1M to $28.0M, a change of −$1.1M. The latest reported quarter, Q2 2026, shows $11.3M.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Zymeworks source filings ↗

Community posts

It’s quiet here.

No posts about ZYME yet. Start the conversation.

Write the first post